Analyst Price Targets — GILD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 8, 2026 11:38 am | — | Morgan Stanley | $166.00 | $136.36 | TheFly | Gilead price target lowered to $166 from $168 at Morgan Stanley |
| July 7, 2026 11:20 am | Brian Abrahams | RBC Capital | $120.00 | $129.61 | TheFly | Gilead price target lowered to $120 from $122 at RBC Capital |
| July 6, 2026 5:35 am | Rajesh Kumar | HSBC | $155.00 | $131.27 | StreetInsider | HSBC Upgrades Gilead Sciences (GILD) to Buy |
| June 1, 2026 11:47 am | Brian Abrahams | RBC Capital | $122.00 | $134.43 | StreetInsider | RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD) |
| May 20, 2026 12:15 pm | Michael Okunewitch | Maxim Group | $165.00 | $130.55 | TheFly | Gilead upgraded to Buy at Maxim on approaching growth drivers, valuation |
| May 10, 2026 2:41 pm | — | Morgan Stanley | $168.00 | $131.33 | TheFly | Gilead price target lowered to $168 from $175 at Morgan Stanley |
| May 8, 2026 1:09 pm | — | Truist Financial | $157.00 | $132.03 | TheFly | Gilead price target raised to $157 from $155 at Truist |
| April 10, 2026 12:53 pm | — | Morgan Stanley | $175.00 | $140.34 | TheFly | Gilead price target raised to $175 from $171 at Morgan Stanley |
| April 8, 2026 12:24 pm | Gregory Renza | Truist Financial | $155.00 | $141.54 | TheFly | Gilead price target raised to $155 from $152 at Truist |
| March 10, 2026 9:37 am | Akash Tewari | Jefferies | $180.00 | $146.94 | StreetInsider | Jefferies Starts Gilead Sciences (GILD) at Buy |
Latest News for GILD
In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day.
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer (NYSE:PFE | PFE Price Prediction) trades at $24.25, against a Wall Street consensus price target of $28.79, which represents implied upside of almost 19%.
Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants in a trial testing Gilead Sciences' experimental antiviral obeldesivir as a post-exposure treatment for the ongoing Bundibugyo Ebola outbreak in Congo and Uganda.
Gilead is seeing success with new oncology and inflammation therapies. The drugmaker went on an acquisition spree this past spring.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.